Abstract
Prospective observational studies have shown that arterial stiffness is a strong and independent predictor of cardiovascular disease in hemodialysis patients. Recent evidence further supports that arterial hardening predicts cardiovascular and all-cause mortality in peritoneal dialysis patients, renal transplant recipients and patients with chronic kidney disease (CKD) not on dialysis. Of note, dissociation of arterial stiffness with blood pressure reduction were related to worsened cardiovascular outcome in kidney disease patients, suggesting that arterial stiffness may not only be a predictor, but also a true risk factor, representing a specific and potentially reversible pattern of outward arterial remodeling in these individuals. On this basis, arterial stiffness has emerged as a novel therapeutic target for cardiovascular risk reduction in patients with CKD; specific interventions, such as renin-angiotensin-system blockade, use of statins, and decrease of calcium- phosphate product may delay the progression of arteriosclerotic process. This article summarizes the accumulated evidence from clinical and epidemiological studies regarding the prognostic significance of arterial stiffening on cardiovascular outcomes and provides insights on possible treatment strategies for arterial stiffness attenuation in patients with CKD.
Keywords: Arterial stiffness, arterial remodeling, chronic kidney disease, end-stage renal disease, cardiovascular morbidity, cardiovascular mortality.
Current Vascular Pharmacology
Title:Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients
Volume: 13 Issue: 2
Author(s): Panagiotis I. Georgianos, Pantelis A. Sarafidis and Anastasios N. Lasaridis
Affiliation:
Keywords: Arterial stiffness, arterial remodeling, chronic kidney disease, end-stage renal disease, cardiovascular morbidity, cardiovascular mortality.
Abstract: Prospective observational studies have shown that arterial stiffness is a strong and independent predictor of cardiovascular disease in hemodialysis patients. Recent evidence further supports that arterial hardening predicts cardiovascular and all-cause mortality in peritoneal dialysis patients, renal transplant recipients and patients with chronic kidney disease (CKD) not on dialysis. Of note, dissociation of arterial stiffness with blood pressure reduction were related to worsened cardiovascular outcome in kidney disease patients, suggesting that arterial stiffness may not only be a predictor, but also a true risk factor, representing a specific and potentially reversible pattern of outward arterial remodeling in these individuals. On this basis, arterial stiffness has emerged as a novel therapeutic target for cardiovascular risk reduction in patients with CKD; specific interventions, such as renin-angiotensin-system blockade, use of statins, and decrease of calcium- phosphate product may delay the progression of arteriosclerotic process. This article summarizes the accumulated evidence from clinical and epidemiological studies regarding the prognostic significance of arterial stiffening on cardiovascular outcomes and provides insights on possible treatment strategies for arterial stiffness attenuation in patients with CKD.
Export Options
About this article
Cite this article as:
Georgianos I. Panagiotis, Sarafidis A. Pantelis and Lasaridis N. Anastasios, Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients, Current Vascular Pharmacology 2015; 13 (2) . https://dx.doi.org/10.2174/15701611113119990147
DOI https://dx.doi.org/10.2174/15701611113119990147 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Novel, Biodegradable, Thermoresponsive Hydrogel Attenuates Ventricular Remodeling and Improves Cardiac Function Following Myocardial Infarction - a review
Current Pharmaceutical Design Cardiovascular Physiology of Androgens and Androgen Testosterone Therapy in Postmenopausal Women
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacological and Lifestyle Factors Modulating Serum Paraoxonase-1 Activity
Mini-Reviews in Medicinal Chemistry Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) Role of Oxidative Stress in Polycystic Ovary Syndrome
Current Women`s Health Reviews Tachykinins and Neuropsychiatric Disorders
Current Drug Targets Nanodiagnostic Attainments and Clinical Perspectives on C-Reactive Protein: Cardiovascular Disease Risks Assessment
Current Medicinal Chemistry Medicinal Chemistry of 2,2,4-Substituted Morpholines
Current Medicinal Chemistry The Anticancer Properties of Dietary Polyphenols and its Relation with Apoptosis
Current Pharmaceutical Design The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part II: Medical Treatment - Study Results
Current Cardiology Reviews Antiplatelet Therapy in Children: Why So Different from Adults’?
Current Pharmaceutical Design Prostacyclin Analogues: Prevention of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Association of flavonoid-rich foods and statins in the management of hypercholesterolemia: a dangerous or helpful combination?
Current Drug Metabolism Allosteric Regulators of the Proteasome: Potential Drugs and a Novel Approach for Drug Design
Current Medicinal Chemistry Inhibitors of HIV-1 Protease: Current State of the Art 10 Years After their Introduction. From Antiretroviral Drugs to Antifungal, Antibacterial and Antitumor Agents Based on Aspartic Protease Inhibitors
Current Medicinal Chemistry Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets 1, 2-Benzisoxazole: A Privileged Structure with a Potential for Polypharmacology
Current Pharmaceutical Design The Relationship Between Diabetes Mellitus, Geriatric Syndromes, Physical Function, and Gait: A Review of the Literature
Current Diabetes Reviews Primary and Secondary Hypertriglyceridaemia
Current Drug Targets Recent Research Progress in Natural Bioactive Constituents against Lipid Metabolic Diseases
Current Topics in Medicinal Chemistry